Recombinant Monkey CD19 Protein, Fc-tagged, Alexa Fluor 647 conjugated
Cat.No. : | CD19-159CAF647 |
Product Overview : | Alexa Fluor 647 conjugated recombinant Rhesus macaque CD19(Pro 20 - Lys 292), fused with Fc of Human IgG1 at C-terminal, was expressed in HEK293. |
Unit | |
Price | |
Qty |
- Specification
- Gene Information
- Related Products
Source : | HEK293 |
Species : | Monkey |
Tag : | Fc |
Form : | Lyophilized |
Molecular Mass : | Has a calculated MW of 56.7 kDa. DTT-reduced Protein migrates as 66-100 kDa in SDS-PAGE due to glycosylation. |
Protein length : | Pro20-Lys292 |
N-terminal Sequence Analysis : | Pro 20 |
Endotoxin : | < 1.0 EU/ μg of the Rhesus Macaque CD19 Fc Chimera by the LAL method. |
Purity : | > 95 % as determined by SDS-PAGE |
Characteristic : | Disulfide-linked homodimer Labeled with Alexa Fluor 647 via amines Excitation = 650 nm Emission = 668 nm |
Storage : | Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at: In lyophilized state for 1 year (4 centigrade); After reconstitution under sterile conditions for 3 months (-70 centigrade). |
Storage Buffer : | Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization. |
Gene Name : | CD19 CD19 molecule [ Homo sapiens ] |
Official Symbol : | CD19 |
Synonyms : | CD19; CD19 molecule; CD19 antigen; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4; B4; CVID3; MGC12802; |
Gene ID : | 930 |
mRNA Refseq : | NM_001178098 |
Protein Refseq : | NP_001171569 |
MIM : | 107265 |
UniProt ID : | P15391 |
Products Types
◆ Lysates | ||
CD19-2005HCL | Recombinant Human CD19 cell lysate | +Inquiry |
CD19-2164MCL | Recombinant Mouse CD19 cell lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (5)
Ask a questionCAR-T cells are engineered to express a receptor that recognizes CD19 on the surface of cancerous B cells. When they encounter these cells, they destroy them.
CD19 deficiencies can lead to primary immunodeficiencies, making individuals more susceptible to infections.
Side effects may include cytokine release syndrome (CRS), neurologic toxicity, and long-term B-cell aplasia.
CAR-T cell therapy is used to treat B-cell malignancies such as acute lymphoblastic leukemia (ALL) and certain types of non-Hodgkin lymphoma.
CAR-T cell therapy has shown remarkable effectiveness in inducing remissions in patients with CD19-positive malignancies, particularly in those who have relapsed or failed conventional treatments.
Customer Reviews (3)
Write a reviewThe manufacturer of CD19 protein has consistently provided outstanding technical support that has surpassed my expectations.
This protein demonstrates remarkable purity, stability, and specificity, ensuring utmost accuracy and reproducibility in my research endeavors.
Their dedication to customer satisfaction has been instrumental in overcoming obstacles and achieving successful results in my experiments.
Ask a Question for All CD19 Products
Required fields are marked with *
My Review for All CD19 Products
Required fields are marked with *
Inquiry Basket